LEVI-04, A NOVEL NEUROTROPHIN-3 INHIBITOR, DEMONSTRATES CLINICALLY MEANINGFUL IMPROVEMENTS IN PAIN AND PHYSICAL FUNCTION ACROSS A RANGE OF OA OUTCOMES, INCLUDING THE OMERACT-OARSI RESPONDER CRITERIA

Osteoarthritis and Cartilage 2026

View at publisher
Authors: Philip Conaghan, Nathaniel Katz, Asger R. Bihlet, Laus W Wullum, Kerry af Forselles, C Michael Perkins, Bernadette Hughes, Claire Herholdt, Iwona Bombelka, Simon L. Westbrook
DOI: 10.1016/j.joca.2026.01.083
Cited by: 1

Fields of Study & Subjects

Neuropeptides and Animal Physiology Peripheral Neuropathies and Disorders Pain Mechanisms and Treatments

Publication details

Journal / source
Osteoarthritis and Cartilage
Publisher
Elsevier BV
Volume
34
Pages
S78–S79
Publication date
1 April 2026
Language
EN